AP-3σ2 Inhibitors
AP-3σ2 inhibitors primarily target vesicle transport processes and cellular trafficking pathways to modulate the activity of AP-3σ2 indirectly. Brefeldin A and Monensin, for instance, can disrupt vesicle trafficking by affecting the structure of the Golgi apparatus and altering ion balance, respectively. These disruptions can influence the vesicular transport that involves the AP-3 complex. Wortmannin, a PI3 kinase inhibitor, can potentially affect vesicle budding and trafficking, implying a potential influence on AP-3σ2. Dynasore acts by inhibiting dynamin, essential for vesicle scission, hence affecting vesicle transport and possibly AP-3σ2.
Furthermore, agents like Nocodazole and Latrunculin A target the cell's cytoskeletal components, such as microtubules and actin, respectively. The proper function of these components is critical for vesicle transport, and any disruption in their activity can indirectly affect the AP-3 complex. Chlorpromazine's mode of action is through its amphiphilic nature, which can interfere with vesicle trafficking and potentially impact AP-3σ2. Similarly, Retro-2 cycl, Pitstop 2, Exo1, SecinH3, and Golgicide A all target various aspects of vesicle transport or endocytosis, implying potential ramifications for AP-3σ2.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $30.00 $52.00 $122.00 $367.00 | 25 | |
Disrupts the structure and function of the Golgi apparatus, potentially affecting vesicle transport involving AP-3. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $152.00 $515.00 | ||
Ionophore that disrupts vesicle trafficking and might indirectly affect AP-3σ2 function. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
PI3 kinase inhibitor which can affect vesicle budding and trafficking, potentially influencing AP-3σ2. | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $87.00 | 44 | |
Inhibits dynamin, a GTPase involved in vesicle scission, which can indirectly affect vesicle transport and AP-3σ2. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $58.00 $83.00 $140.00 $242.00 | 38 | |
Disrupts microtubules and can affect vesicle transport, indirectly influencing the AP-3 complex. | ||||||
Latrunculin A, Latrunculia magnifica | 76343-93-6 | sc-202691 sc-202691B | 100 µg 500 µg | $260.00 $799.00 | 36 | |
Disrupts actin polymerization, which can influence vesicle transport and might affect the AP-3 complex. | ||||||
Chlorpromazine | 50-53-3 | sc-357313 sc-357313A | 5 g 25 g | $60.00 $108.00 | 21 | |
Cationic amphiphilic drug that affects vesicle trafficking, potentially influencing AP-3σ2. | ||||||
Pitstop 2 | 1419093-54-1 | sc-507418 | 10 mg | $360.00 | ||
Clathrin terminal domain inhibitor which can affect clathrin-mediated endocytosis, possibly influencing AP-3σ2. | ||||||
SecinH3 | 853625-60-2 | sc-203260 | 5 mg | $273.00 | 6 | |
Disrupts the function of cytohesin ARF GEFs, which can impact vesicle trafficking and AP-3σ2 function. | ||||||
Golgicide A | 1005036-73-6 | sc-215103 sc-215103A | 5 mg 25 mg | $187.00 $670.00 | 11 | |
A specific inhibitor of the ARF1 GEF GBF1, potentially affecting vesicle trafficking and AP-3σ2. | ||||||